Everest Medicines' proprietary mRNA-based therapeutic tumor vaccine, EVM14, has secured Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA), officially initiating its global clinical trial phase. This milestone represents Everest Medicines' pioneering venture into the realm of mRNA tumor vaccines with its first ready-to-use, universal tumor vaccine.
